Production and in vitro characterization of lisinopril-loaded nanoparticles for the treatment of restenosis in stented coronary arteries

Journal of Microencapsulation

Volumn 25, Issue 7, 2008, Pages 478-486

  Varshosaz, J ^a,b   Soheili, M ^a,b  

^a Isfahan Pharmaceutical Sciences Research Center   (Iran)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

ACE inhibitor; Lisinopril; PLGA; Polymeric nanoparticles; Restenosis

Indexed keywords

LISINOPRIL; NANOPARTICLE; POLOXAMER; POLYGLACTIN; POLYVINYL ALCOHOL;

ARTICLE; CORONARY STENT; DIFFUSION; DRUG CAPSULE; DRUG COATING; DRUG FORMULATION; DRUG RELEASE; DRUG STABILITY; EMULSION; IN VITRO STUDY; NANOENCAPSULATION; NANOENGINEERING; NANOTECHNOLOGY; PARTICLE SIZE; RESTENOSIS; ZETA POTENTIAL;

ABSORBABLE IMPLANTS; CARDIOTONIC AGENTS; CORONARY RESTENOSIS; CORONARY VESSELS; HUMANS; LACTIC ACID; LISINOPRIL; MICROSCOPY, ELECTRON, SCANNING; NANOPARTICLES; POLYGLYCOLIC ACID; STENTS;

EID: 54049156456     PISSN: 02652048     EISSN: 14645246     Source Type: Journal    
DOI: 10.1080/02652040802054679     Document Type: Article

References (35)

1. Baker, RW and Lonsdale, HK (1974) Controlled release: Mechanisms and rates. Controlled release of biologically active agents, pp. 15-71. Plenum Press, New York
2. Banai, S., Chorny, M., Gertz, SD, Fishbein, I., Gao, J., Perez, L., Lazarovichi, G., Gazit, A., Levitzki, A. and Golomb, G. (2005) Locally delivered nanoencapsulated tyrphostin (AGL-2043) reduces neointima formation in balloon-injured rat carotid and stented porcine coronary arteries. Biomaterials, 26, pp. 451-461.
3. Binks, BP and Lumsdon, SO (2000) Influence of particle wettability on the type and stability of surfactant-free emulsions. Langmuir, 16, pp. 8622-8631.
4. Budhian, A., Siegel, SJ and Winey, KI (2008) Controlling the in vitro release profiles for a system of haloperidol-loaded PLGA nanoparticles. Int J Pharm, 346, pp. 151-159.
5. Chorny, M., Fishbein, I. and Golomb, G. (2000) Drug delivery systems for the treatment of restenosis. Crit Rev Ther Drug Carrier Syst, 17, pp. 49-284.
6. Eccleston, DS and Lincoff, AM (1997) Catheter-based drug delivery for restenosis. Adv Drug Deliv Rev, 24, pp. 31-43.
7. El-Gindy, A., Ashour, A., Abdel-Fattah, L. and Shabana, MM (2001) Spectrophotometric, septrofluorimetric and LC determination of lisinopril. J Pharm Biomed Anal, 25, pp. 913-922.
8. Ettenson, DS and Edelman, ER (2000) Local drud delivery: An emerging approach in the treatment of restenosis. Vasc Med, 5, pp. 97-102.
9. Fishbein, I., Chorny, M., Banai, S., Levitzki, A., Danenberg, HD, Gao, J., Chen, X., Moerman, E., Gati, I. Goldwasser, V. et al. (2001) Formulation and delivery mode affect disposition and activity of tyrphostin-loaded nanoparticles in the rat carotid model. Arterioscler Thromb Vasc Biol, 21, pp. 1434-1439.
10. Gershlick, AH (2002) Treating atherosclerosis: Local drug delivery from laboratory studies to clinical trials. Atherosclerosis, 160, pp. 259-271.
11. 2 factorial design. Drug Dev Ind Pharm, 28, pp. 77-87.
12. Gupta, KC and Jabrail, FH (2006) Glutaraldehyde and glyoxal cross-linked chitosan microspheres for controlled delivery of centchroman. Carbohyd Res, 341, pp. 744-756.
13. Guzman, LA, Labhasetwar, V., Song, C., Jang, Y., Lincoff, AM, Levy, R. and Topol, EJ (1996) Local intraluminal infusion of biodegradable polymeric nanoparticles - a novel approach for prolonged drug delivery after balloon angioplasty. Circulation, 94, pp. 1441-1448.
14. Haskell, RJ (2006) Physical characterization of nanoparticles. Nanoparticle technology for drug delivery, pp. 119-120. Taylor & Francis Group, New York
15. Higuchi, T. (1963) Mechanism of sustained-action medication. Theoretical analysis of rate of release of solid drugs dispersed in solid matrices. J Pharm Sci, 52, pp. 1145-1149.
16. Hixson, AW and Crowell, JH (1931) Dependence of reaction velocity upon surface and agitation. I. Theoretical consideration. Ind Eng Chem, 23, pp. 923-931.
17. Itoh, T., Nonogi, H., Miyazaki, S., Itoh, A., Daikoku, S., Morii, I. and Goto, Y. (2004) Local delivery of argatroban for the prevention of restenosis after coronary balloon angioplasty: A propective randomized pilot study. Circulat J, 68, pp. 615-622.
18. Kavanagh, CA, Rochev, YA, Gallagher, WM, Dawson, KA and Keenan, AK (2004) Local drug delivery in restenosis injury: Thermoresponsive co-polymers as potential drug delivery systems. Pharmacol Ther, 102, pp. 1-15.
19. Kawaguchi, H. (2000) Functional polymer microspheres. Prog Polym Sci, 25, pp. 1171-1210.
20. Kronberg, B., Kall, L. and Stenius, P. (1981) Adsorption of nonionic surfactants on latexes. J Dispersion Sci Tech, 2, pp. 215-232.
21. Labhasetwar, V. and Levy, RJ (1991) Implants for site-specific drug delivery. J App Biomat, 2, pp. 211-212.
22. Labhasetwar, V., Song, C., Humphrey, W., Shebuski, R. and Levy, RJ (1998) Arterial uptake of biodegradable nanoparticles: Effect of surface modifications. J Pharm Sci, 87, pp. 1229-1234.
23. Labhasetwar, V., Song, CX and Levy, RJ (1997) Nanoparticle drug delivery systems for restenosis. Adv Drug Del Rev, 24, pp. 63-85.
24. Leroux, JC, Allemann, E., Gurny, R. and Doelker, E. (1995) New approach for the preparation of nanoparticles by an emulsification-diffusion method. Eur J Pharm Biopharm, 41, pp. 14-18.
25. Li Wan Po, A, Wong, LP and Gilligan, CA (1990) Characterisation of commercially available theophylline sustained- or controlled-release systems: In vitro drug release profiles. Int J Pharm, 66, pp. 111-130.
26. Lincoff, AM, Topol, EJ and Ellis, SG (1994) Local drug delivery for the prevention of restenosis: Fact, fancy, and future. Circulation, 90, pp. 2070-2084.
27. Ren, S., Park, MJ, Sah, H. and Lee, BJ (2008) Effect of pharmaceutical excipients on aqueous stability of rabeprazole sodium
28. Rensing, BJ, Vos, J., Smits, PC, Foley, DP, Van den Brand, MJ, Van der Giessen, WJ, de Feijter, PJ and Serrys, PW Coronary restenosis elimination with a sirolimos elutingstent - First European human experience with 6-month angiographic and intravascular ultrasonic follow-up. Eur Heart J, 22, pp. 2125-2130.
29. Sagirli, O. and Ersoy, L. (2004) An HPLC method for the determination of lisinopril in human plasma and urine with fluorescence detection. J Chromatog B, 809, pp. 159-165.
30. Song, CX, Labhasetwar, V., Murphy, H., Qu, X., Humphrey, WR, Shebuski, RJ and Levy, RJ (1997) Formulation and characterization of biodegradable nanoparticles for intravascular local drug delivery. J Contr Rel, 43, pp. 197-212.
31. Sturek, M. and Reddy, HK (2002) New tools for prevention of restenosis could decrease the 'oculo-stento' reflex. Cardiovasc Res, 53, pp. 292-293.
32. Tambe, DE and Sharma, MM (1994) The effect of colloidal particles on fluid-fluid interfacial properties and emulsion stability. J Colloid Interface Sci, 52, pp. 1-63.
33. Tep, G., Duda, SH, Kalinowski, M., Kamenz, J., Brehme, U., Hanke, H., Claussen, CD, Bares, R., Baumbach, A. and Dinkelborg, LM (2001) Local intra-arterial drug delivery for prevention of restenosis: Comparison of the efficiency of delivery of different radiopharmaceuticals through a porous catheter. Invest Radiol, 36, pp. 245-249.
34. Vijayaraghavan, K. and Deedwania, PC (2005) The rennin angiotensin system as a therapeutic target to prevent diabetes and its complications. Cardiol Clin, 23, pp. 165-183.
35. Zweers, MLT, Engbers, GHM, Grijpma, DW and Feijen, J. (2006) Release of anti-restenosis drugs from poly(ethylene oxide)-poly(dl-lactic-co-glycolic acid) nanoparticles. J Contr Rel, 114, pp. 317-324.